Molecular structure pattern

Rheumatoid Arthritis References

Last updated: 26 October 2026
Reviewed by
  1. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. http://ard.bmj.com/content/early/2015/05/12/annrheumdis-2015-207524.full.pdf. Accessed 04 Sep 2015. PMID: 25969430
  2. Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Accessed 06 Jun 2016. PMID: 26545825
  3. McInnes IB. Cytokine networks in rheumatic diseases: implications for therapy. UpToDate. http://www.uptodate.com. Aug 2018. Accessed 28 Sep 2018.
  4. Moreland LW, Cannella A. General principles of management of rheumatoid arthritis in adults. UpToDate. https://www.uptodate.com. May 2018. Accessed 28 Sep 2018.
  5. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Accessed 28 Sep 2018. PMID: 27156434
  6. England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555. doi: 10.1002/acr.24042. Accessed 24 Feb 2020. PMID: 31709779
  7. Ministry of Health Malaysia, Malaysian Society of Rheumatology, Academy of Medicine Malaysia. Clinical practice guidelines. Management of rheumatoid arthritis. Academy of Medicine of Malaysia. http://www.acadmed.org.my. 2019. Accessed 04 Feb 2020.
  8. U.S. Food & Drug Administration (US FDA). Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
  9. New long-term data from Rinvoq (Upadacitinib, 15 mg) phase 3 studies in rheumatoid arthritis presented at 2020 Annual European E-Congress of Rheumatology (EULAR). Abbvie News Center. https://news.abbvie.com/. 04 Jun 2020. Accessed 06 Jun 2020.
  10. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. Accessed 06 Jun 2020. PMID: 28199814
  11. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Accessed 06 Jul 2020. PMID: 31413005
  12. Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis?. Semin Immunopathol. 2017 Jun;39(4):487-500. doi: 10.1007/s00281-017-0623-3. Accessed 09 Jul 2020. PMID: 28451787
  13. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Accessed 09 Jul 2020. PMID: 28629665
  14. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Accessed 09 Jul 2020. PMID: 31287230
  15. Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016 Sep;2(2):e000308. doi: 10.1136/rmdopen-2016-000308. Accessed 09 Jul 2020. PMID: 27752357
  16. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Accessed 23 Sep 2021. PMID: 34101387
  17. Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020 Oct;383(16):1511-1521. doi: 10.1056/nejmoa2008250. PMID: 33053283
  18. Adam Rindfleisch J, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005 Sep 15;72(6):1037-1047. https://www.aafp.org.
  19. American College of Rheumatology (ACR). 2022 American College of Rheumatology (ACR) guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis guideline summary. ACR. https://www.rheumatology.org. 31 Oct 2022.
  20. Chauhan K, Jandu JS, Goyal A, et al. Rheumatoid arthritis. StatPearls. https://www.ncbi.nlm.nih.gov. 04 Jun 2022.
  21. England BR, Mikuls TR. Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis. UpToDate. https://www.uptodate.com. 08 Aug 2022. Accessed 05 Dec 2022.
  22. Hidayat R, Suryana BPP, Wijaya LK, et al. Indonesian Rheumatology Association (IRA) recommendations for diagnosis and management of rheumatoid arthritis. Ina J Rheum. 2021;13(1):322-443. https://journalrheumatology.or.id/.
  23. Ho CTK, Mok CC, Cheung TT, et al. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2019 Dec;38(12):3331-3350. doi: 10.1007/s10067-019-04761-5. PMID: 31485846
  24. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. PMID: 36357155
  25. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018 Oct;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Accessed 16 Aug 2023. PMID: 30285183
  26. Caporali R, Aletaha D, Sanmarti R, et al. Long-term efficacy of Baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment. Ann of Rheum Dis. 2022;81(Suppl 1):630-631. doi: 10.1136/annrheumdis-2022-eular.4546.
  27. Currier BL, Coblyn J. Cervical subluxation in rheumatoid arthritis. UpToDate. https://www.uptodate.com. 08 Dec 2021.
  28. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi: 10.1136/annrheumdis-2016-2100.
  29. England BR, Smith BJ, Baker NA, et al. 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023 Aug;75(8):1603-1615. doi: 10.1002/acr.25117. PMID: 37227116
  30. National Institute for Health and Care Excellence (NICE). Rheumatoid arthritis in adults: management. NICE. https://www.nice.org.uk/. 12 Oct 2020.
  31. Smolen JS, Aletaha D. Assessment of rheumatoid arthritis disease activity and physical function. UpToDate. https://www.uptodate.com. 22 Nov 2022.
  32. Smolen JS. Undifferentiated early inflammatory arthritis in adults. UpToDate. https://www.uptodate.com. 28 May 2022.
  33. Ito H, Nishida K, Kojima T, et al. Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis – secondary publication. Mod Rheumatol. 2023 Jan;33(1):35-45. doi: 10.1093/mr/roac019. PMID: 35294030
  34. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 2023 Jan;75(1):15-22. doi: 10.1002/art.42347. PMID: 36274193
  35. Baker J. Diagnosis and differential diagnosis of rheumatoid arthritis. UpToDate. https://www.uptodate.com/. 21 Mar 2024.
  36. Cohen S, Mikuls T. Initial treatment of rheumatoid arthritis in adults. UpToDate. https://www.uptodate.com. 05 Jan 2024. Accessed 02 May 2024.
  37. Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: Pathogenesis and therapeutic advances. MedComm (2020). 2024 Apr;5(3):e509. doi: 10.1002/mco2.509. PMID: 38469546
  38. Electronic Medicines Compendium (EMC). Jyseleca. EMC. https://www.medicines.org.uk/. 24 Jan 2024. Accessed 28 Jun 2024.
  39. Cohen S, Reddy V. Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders. UpToDate. https://www.uptodate.com/. 04 May 2024.
  40. Burmester GR, Gottenberg JE, Caporali R, et al. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Ann Rheum Dis. 2024 May;10:ard-2024-225759. doi: 10.1136/ard-2024-225759. PMID: 38782549
  41. Tanaka Y, Genovese MC, Matsushima H. Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: Current perspectives. Patient Prefer Adherence. 2023 Oct;6(17):2499-2516. doi: 10.2147/PPA.S417677. Accessed 28 Jun 2024. PMID: 37822545
  42. Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026 Jun;85(6):991-1009. doi: 10.1016/j.ard.2026.01.023. PMID: 41826212